Lundbeck fails with Phase III trial of idalopirdine in Alzheimer's

23 September 2016

Denmark-based CNS specialist Lundbeck (LUND: CO) suffered a 14% drop in its share price on Friday morning after announcing that a Phase III study of idalopirdine for the symptomatic treatment of patients with mild to moderate Alzheimer's disease had failed to meet its endpoint.

In the Starshine study, idalopirdine showed a weak efficacy profile, as neither of the two dosages used met the primary endpoint of a reduction in the Alzheimer's disease assessment scale-cognitive subscale total score, when added to donepezil.

In addition, the secondary endpoints also did not show separation from placebo. The overall safety profile for idalopirdine showed that it was safe and well tolerated. Further analysis of the data is ongoing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK